Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

Novo Nordisk A/S (NVO) investors who had anticipated ... Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to ...

The drug cost $219 for a month’s supply, a fraction of the list price of $968 for a month’s supply of Ozempic in the U.S. The owners of the home in Boulder say they have no connection to the ...

Novo Nordisk (NYSE: NVO) took a hit on its stock price last week after it received bad news on one of its in-development ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Oct 21 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a ...

For many patients with type 2 diabetes, having to inject basal insulin every day is a burdensome fact of life, but Novo Nordisk is trying ... providing a background level of blood glucose control ...

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week. Wegovy has been FDA-approved ...

Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...

Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the pharmaceutical giant's third quarter results could show a slowing in sales of ...

Bernstein analyst Florent Cespedes maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK560.00. The company’s shares closed last Friday at ...